Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver

Drug Metabolism and Disposition

Volumn 36, Issue 10, 2008, Pages 2113-2120

  Kassner, Nina ^a   Huse, Klaus ^b   Martin, Hans Jörg ^c   Gödtel Armbrust, Ute ^a   Metzger, Annegret ^a   Meineke, Ingolf ^d   Brockmöller, Jürgen ^d   Klein, Kathrin ^e,f   Zanger, Ulrich M ^e,f   Maser, Edmund ^c   Wojnowski, Leszek ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b FRITZ LIPMANN INSTITUTE   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^f UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONYL REDUCTASE; CARBONYL REDUCTASE 1; DOXORUBICIN; DOXORUBICINOL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DISPOSITION; DRUG DISTRIBUTION; ENZYME SUBSTRATE; GASTROINTESTINAL TRACT; HAPLOTYPE; HEART FAILURE; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY; LIVER; LIVER CYTOSOL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ALCOHOL OXIDOREDUCTASES; BIOPSY; BLOTTING, WESTERN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOXORUBICIN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME INHIBITORS; HUMANS; LIVER; POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 52949118777     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.022251     Document Type: Article

References (40)

1. Bains OS, Takahashi RH, Pfeifer TA, Grigliatti TA, Reid RE, and Riggs KW (2008) Two allelic variants of aldo-keto reductase 1A1 exhibit reduced in vitro metabolism of daunorubicin. Drug Metab Dispos 36:904-910.
2. Burczynski ME, Harvey RG, and Penning TM (1998) Expression and characterization of four recombinant human dihydrodiol dehydrogenase isoforms: oxidation of trans-7, 8-dihydroxy-7,8-dihydrobenzo[a]pyrene to the activated o-quinone metabolite benzo[a]pyrene-7,8-dione. Biochemistry 37:6781-6790.
3. Byrns MC, Steckelbroeck S, and Penning TM (2008) An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies. Biochem Pharmacol 75:484-493.
4. Covarrubias VG, Lakhman SS, Forrest A, Relling MV, and Blanco JG (2006) Higher activity of polymorphic NAD(P)H:quinone oxidoreductase in liver cytosols from blacks compared to whites. Toxicol Lett 164:249-258.
5. Cusack BJ, Young SP, Driskell J, and Olson RD (1993) Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. Cancer Chemother Pharmacol 32:53-58.
6. Doorn JA, Maser E, Blum A, Claffey DJ, and Petersen DR (2004) Human carbonyl reductase catalyzes reduction of 4-oxonon-2-enal. Biochemistry 43:13106-13114.
7. Dorr RT, Shipp NG, and Lee KM (1991) Comparison of cytotoxicity in heart cells and tumor cells exposed to DNA intercalating agents in vitro. Anticancer Drugs 2:27-33.
8. Ferrazzi E, Woynarowski JM, Arakali A, Brenner DE, and Beerman TA (1991) DNA damage and cytotoxicity induced by metabolites of anthracycline antibiotics, doxorubicin and idarubicin. Cancer Commun 3:173-180.
9. Forrest GL, Gonzalez B, Tseng W, Li X, and Mann J (2000) Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice. Cancer Res 60:5158-5164.
10. Frost BM, Eksborg S, Björk O, Abrahamsson J, Behrendtz M, Castor A, Forestier E, and Lönnerholm G (2002) Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study. Med Pediatr Oncol 38:329-337.
11. Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57:727-741.
12. Hoffmann F and Maser E (2007) Carbonyl reductases and pluripotent hydroxysteroid dehydro-genases of the short-chain dehydrogenase/reductase superfamily. Drug Metab Rev 39:87-144.
13. Joerger M, Huitema AD, Meenhorst PL, Schellens JH, and Beijnen JH (2005) Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. Cancer Chemother Pharmacol 55:488-496.
14. Krook M, Ghosh D, Duax W, and Jörnvall H (1993a) Three-dimensional model of NAD( + )- dependent 15-hydroxyprostaglandin dehydrogenase and relationships to the NADP(+)- dependent enzyme (carbonyl reductase). FEBS Lett 322:139-142.
15. Krook M, Ghosh D, Strömberg R, Carlquist M, and Jörnvall H (1993b) Carboxyethyllysine in a protein: native carbonyl reductase/NADP( + )-dependent prostaglandin dehydrogenase. Proc Natl Acad Sci USA 90:502-506.
16. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
17. Lakhman SS, Chen X, Gonzalez-Covarrubias V, Schuetz EG, and Blanco JG (2007) Functional characterization of the promoter of human carbonyl reductase 1 (CBR1). Role of XRE elements in mediating the induction of CBR1 by ligands of the aryl hydrocarbon receptor. Mol Pharmacol 72:734-743.
18. Lee YT, Chan KK, Harris PA, and Cohen JL (1980) Distribution of adriamycin in cancer patients: tissue uptakes, plasma concentration after IV and hepatic IA administration. Cancer 45:2231-2239.
19. Lovless H, Arena E, Felsted RL, and Bachur NR (1978) Comparative mammalian metabolism of adriamycin and daunorubicin. Cancer Res 38:593-598.
20. Martin HJ, Breyer-Pfaff U, Wsol V, Venz S, Block S, and Maser E (2006) Purification and characterization of akr1b10 from human liver: role in carbonyl reduction of xenobiotics. Drug Metab Dispos 34:464-470.
21. Menna P, Minotti G, and Salvatorelli E (2007) In vitro modeling of the structure-activity determinants of anthracycline cardiotoxicity. Cell Biol Toxicol 23:49-62.
22. Minotti G, Menna P, Salvatorelli E, Cairo G, and Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185-229.
23. Mordente A, Minotti G, Martorana GE, Silvestrini A, Giardina B, and Meucci E (2003) Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications. Biochem Pharmacol 66:989-998.
24. O'Connor T, Ireland LS, Harrison DJ, and Hayes JD (1999) Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members. Biochem J 343(Pt 2):487-504.
25. Ohara H, Miyabe Y, Deyashiki Y, Matsuura K, and Hara A (1995) Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver. Biochem Pharmacol 50:221-227.
26. Olson LE, Bedja D, Alvey SJ, Cardounel AJ, Gabrielson KL, and Reeves RH (2003) Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1. Cancer Res 63:6602-6606.
27. Olson RD and Mushlin PS (1990) Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 4:3076-3086.
28. Olson RD, Mushlin PS, Brenner DE, Fleischer S, Cusack BJ, Chang BK, and Boucek RJ Jr (1988) Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci USA 85:3585-3589.
29. Palle J, Frost BM, Peterson C, Gustafsson G, Hellebostad M, Kanerva J, Schmiegelow K, and Lönnerholm G (2006) Doxorubicin pharmacokinetics is correlated to the effect of induction therapy in children with acute myeloid leukemia. Anticancer Drugs 17:385-392.
30. Preisler HD, Gessner T, Azarnia N, Bolanowska W, Epstein J, Early AP, D'Arrigo P, Vogler R, Winton L, Chervenik P, et al. (1984) Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia. Cancer Chemother Pharmacol 12:125-130.
31. Rosemond MJ and Walsh JS (2004) Human carbonyl reduction pathways and a strategy for their study in vitro. Drug Metab Rev 36:335-361.
32. Sacco G, Giampietro R, Salvatorelli E, Menna P, Bertani N, Graiani G, Animati F, Goso C, Maggi CA, Manzini S, et al. (2003) Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity. Br J Pharmacol 139:641-651.
33. Salvatorelli E, Guarnieri S, Menna P, Liberi G, Calafiore AM, Mariggiò MA, Mordente A, Gianni L, and Minotti G (2006) Defective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart. Relative importance of vesicular sequestration and impaired efficiency of electron addition. J Biol Chem 281:10990-11001.
34. Scripture CD, Sparreboom A, and Figg WD (2005) Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol 6:780-789.
35. Stewart DJ, Grewaal D, Green RM, Mikhael N, Goel R, Montpetit VA, and Redmond MD (1993) Concentrations of doxorubicin and its metabolites in human autopsy heart and other tissues. Anticancer Res 13:1945-1952.
36. Takahashi RH, Bains OS, Pfeifer TA, Grigliatti TA, Reid RE, and Riggs KW (2008) Aldo-keto reductase 1C2 fails to metabolize doxorubicin and daunorubicin in vitro. Drug Metab Dispos 36:991-994.
37. Tanaka M, Bateman R, Rauh D, Vaisberg E, Ramachandani S, Zhang C, Hansen KC, Burlingame AL, Trautman JK, Shokat KM, et al. (2005) An unbiased cell morphology-based screen for new, biologically active small molecules. PLoS Biol 3:e128.
38. Wermuth B, Bohren KM, and Ernst E (1993) Autocatalytic modification of human carbonyl reductase by 2-oxocarboxylic acids. FEBS Lett 335:151-154.
39. Wihlm J, Limacher JM, Levêque D, Duclos B, Dufour P, Bergerat JP, and Methlin G (1997) [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients]. Bull Cancer 84:603-608.
40. Wolbold R, Klein K, Burk O, Nüssler AK, Neuhaus P, Eichelbaum M, Schwab M, and Zanger UM (2003) Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38:978-988.